{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Treatment Emergent SAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Treatment Emergent Treatment Related AEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"3"}]}],"title":"Treatment Emergent Treatment Related SAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"4"}],"units":"Participants"}],"description":"An AE was defined as any untoward medical occurrence in a participant temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs included both serious and all non-serious adverse events. An SAE was defined as any untoward medical occurrence that, at any dose resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or that was considered as an important medical event. A TEAE was defined as an AE that first occurred from the first dose of the study intervention until 90 days after the last dose or the day before starting a new anticancer therapy, whichever occurred first. Treatment related AEs and SAEs were defined as AEs and SAEs which was related to the treatment.","groups":[{"description":"Participants received an initial priming dose of 600 microgram per kilogram elranatamab subcutaneously on Cycle 0 Day 1 (7 days prior to Cycle 1 Day 1). During treatment cycle, participants were administered 1000 microgram per kilogram elranatamab weekly during each cycle (each cycle was of 3 weeks).","id":"OG000","title":"Elranatamab"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"SAS included all enrolled participants who received at least 1 dose of study intervention.","reportingStatus":"POSTED","timeFrame":"From first dose of study intervention and up to 90 days after last dose or start of new anticancer therapy (maximum of 65.1 weeks of treatment)","title":"Number of Participants With Treatment Emergent Adverse Events (TEAEs), Treatment Emergent Serious Adverse Events (SAEs), Treatment Emergent Treatment Related AEs and Treatment Emergent Treatment Related SAEs","type":"SECONDARY","unitOfMeasure":"Participants"}